Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
APGE reported a Form 144 notifying the sale of 6,000 restricted shares of Common Stock by Jane Henderson. The filing lists four 10b5-1 sales across 01/02/2026, 01/06/2026, 02/02/2026, and 03/02/2026 with per-trade share counts of 6,000, 2,000, 2,000 and 2,000 respectively and reported proceeds per trade in the filing.
Apogee Therapeutics, Inc. is offering $300,000,000 of its voting common stock in a registered underwritten offering, with the underwriters holding a 30-day option to purchase an additional $45,000,000 of shares.
The prospectus supplement states proceeds will be received by the issuer and that net proceeds are intended to fund preclinical studies, clinical trials, manufacturing, commercial readiness, research and development, capital expenditures, working capital and general corporate purposes. Shares outstanding were 69,038,943 as of December 31, 2025.
Apogee Therapeutics reported positive 52-week maintenance results from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis. At 3- and 6‑month dosing intervals, 75% and 85% of patients maintained EASI‑75, and 86% and 78% maintained vIGA 0/1, showing durable disease control with infrequent injections.
The 360 mg subcutaneous regimen produced deepening responses across lesion and itch endpoints in both initial 16‑week responders and the full treated population, with a safety profile generally in line with other agents in the class. APEX Part B, a 347‑patient, placebo‑controlled dose‑optimization study, is expected to deliver 16‑week data in the second quarter of 2026.
Based on these data and the anticipated Part B induction results, the company plans to start Phase 3 trials in the second half of 2026, targeting a potential commercial launch in 2029 in what it believes could be a $50 billion atopic dermatitis market.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on March 11, 2026 at weighted average prices reported as $74.29, $74.83, and $75.86 per share, across multiple trades within disclosed price ranges.
The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the reported sales, Henderson directly holds 1,152,987 shares of Apogee Therapeutics Common Stock, indicating he retains a large remaining equity position.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported option exercises and share sales. On March 4, 2026, he exercised stock options for 4,125 shares and acquired 4,125 shares of common stock at $22.86 per share. He then sold a total of 5,500 common shares in three open-market transactions at weighted average prices of $70.33, $71.98 and $73.26 per share, executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Following these trades, he held 209,773 shares of Apogee Therapeutics common stock directly.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,213,827 shares of Apogee Therapeutics Inc common stock, representing 11.3% of the class as of 02/28/2026. The filing shows sole voting power for 5,879,389 shares and sole dispositive power for 6,206,591 shares. The T. Rowe Price Capital Appreciation Fund is identified as holding 3,290,061 shares (6.0%).
Apogee Therapeutics Chief Financial Officer Jane Henderson reported selling 2,000 shares of Apogee Therapeutics common stock in a series of open-market transactions on March 2, 2026. The sales, coded as open-market transactions, occurred at weighted average prices of $68.27, $69.43, $70.45 and $71.66, with each price reflecting multiple trades within stated ranges. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 2, 2025. After the final sale, Henderson directly held 181,371 shares of Apogee Therapeutics common stock.
Apogee Therapeutics, Inc. provides an annual update on its inflammatory and immunology biologics pipeline, led by zumilokibart (APG777) for atopic dermatitis and asthma. The company reports strong Phase 2 APEX Part A results in moderate‑to‑severe atopic dermatitis, with a 71.0% mean EASI reduction at Week 16 versus 33.8% on placebo and 66.9% of patients achieving EASI‑75 versus 24.6% on placebo.
Zumilokibart and other antibodies in the portfolio show extended half-lives of 55 to 77 days, supporting dosing every three to six months and favorable safety profiles across early trials. Apogee is also advancing combination programs APG279 (IL‑13 + OX40L) and APG273 (IL‑13 + TSLP), and APG808 targeting IL‑4Rα, across atopic dermatitis, asthma, eosinophilic esophagitis and COPD.
The aggregate market value of non‑affiliate equity was approximately $1,757.9 million as of June 30, 2025. As of February 23, 2026, Apogee had 69,485,247 common shares outstanding, split between 55,998,605 voting and 13,486,642 non‑voting shares.
Apogee Therapeutics reported a larger full-year 2025 net loss of $255.8 million, up from $182.1 million in 2024, as it increased investment in its pipeline. Research and development expenses rose to $214.7 million and general and administrative expenses to $70.9 million.
The company ended 2025 with cash, cash equivalents and marketable securities totaling $902.9 million, and it believes this will fund operations into the second half of 2028. Key zurmilokibart (APG777) milestones include APEX Phase 2 Part A 52-week data expected in March, Part B data in Q2 2026, and Phase 3 initiation in atopic dermatitis in the second half of 2026, alongside a head-to-head APG279 trial versus DUPIXENT with results expected in the second half of 2026.
RTW Investments, LP and its managing partner Roderick Wong, M.D. report beneficial ownership of Apogee Therapeutics common stock. They disclose indirect control over 2,712,097 shares, representing 4.9% of the outstanding common stock, based on 54,833,587 shares outstanding as of November 3, 2025.
The shares are held by RTW-managed funds, with RTW and Dr. Wong sharing voting and dispositive power and no sole authority. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Apogee Therapeutics.